TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05597683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Description: Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids
Study: NCT05280470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
Study: NCT05556746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Daily therapy for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Daily therapy for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Daily therapy for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Daily therapy for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Daily therapy for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Daily therapy for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Daily therapy for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Daily therapy for 8 weeks
Study: NCT06236724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Given by PO
Study: NCT05263453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
Study: NCT06149702

Intervention type: OTHER
Group type: OTHER
Intervention: Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet
Description: KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet
Description: KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.
Study: NCT06474377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 1
Description: One dose of Sinovac PCV24 formulation 1（0.5mL）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 2
Description: One dose of Sinovac PCV24 formulation 2（0.5mL）

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax®
Description: One dose of Pneumovax® (0.5 mL) contains 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F saccharides.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of 0.9%NaCl solution (normal saline)
Study: NCT06555731

Intervention type: GENETIC
Intervention: Ultra rapid genome sequencing
Description: DNA extraction from blood sample and whole genome sequencing
Study: NCT04227288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar Foam
Description: Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
Study: NCT05656027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine + Brimonidine
Description: LNZ101 (Aceclidine/Brimonidine) ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine
Description: LNZ100 Aceclidine ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: Brimonidine ophthalmic solution
Study: NCT05112302

Intervention type: OTHER
Intervention: Virtual reality
Description: Use of virtual reality goggles during procedure
Study: NCT05125692

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal surgical repair of isthmocele
Description: after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
Study: NCT06258837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DISE-Directed Surgery
Description: Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy
Description: Tonsil and/or adenoid removal
Study: NCT06115967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.
Study: NCT04672538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Vt protocol
Description: Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Vt protocol
Description: Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Vt protocol
Description: High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
Study: NCT06115967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6912
Description: AZD6912 will be administered as a single sub-cutaneous dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single sub-cutaneous dose.
Study: NCT06653218

Intervention type: OTHER
Intervention: No interventions
Description: It is a observational study

Intervention type: OTHER
Intervention: Not have interventions
Description: It is a observational study
Study: NCT04832438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
Study: NCT06644781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan hydrochloride (HCl)
Description: Intravenous administration
Study: NCT04784416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPBM-2.0
Description: The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
Study: NCT04672538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Vt protocol
Description: High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
Study: NCT06403774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)
Description: A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )
Description: An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
Study: NCT06057558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic throat spray
Description: Throat spray containing Lacticaseibacillus casei AMBR2
Study: NCT04784416

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tPBM-2.0
Description: The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 18F-MK-6240
Description: PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
Study: NCT05630066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg QD Alogabat
Description: Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.~I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg QD Alogabat
Description: Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
Study: NCT06340204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection
Description: Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection
Description: Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
Study: NCT05630066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 mg QD Alogabat
Description: Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Adult Alogabat High Dose (aged 15-17)
Description: In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogabat
Description: In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
Study: NCT06228326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus
Study: NCT05630066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogabat
Description: If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Optional Cohort
Description: If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2
Study: NCT06423599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Weight loss using Semaglutide

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet
Description: Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
Study: NCT06606990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pidnarulex
Description: Given IV
Study: NCT06377215

Intervention type: DEVICE
Intervention: Open-source master hearing aid
Description: The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
Study: NCT06623006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health (mhealth)
Description: The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
Study: NCT06415760

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
Study: NCT06693908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified.
Study: NCT06693830

Intervention type: DEVICE
Group type: OTHER
Intervention: Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
Description: PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
Description: PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for cycles 1-6

Intervention type: OTHER
Group type: OTHER
Intervention: De-escalated Treatment
Description: Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
Study: NCT06228326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: PD-1 immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: PD-1 immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: SOC chemotherapy
Study: NCT05002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
Study: NCT05779527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting Programme
Description: Online Mindful Parenting Programme with group support sessions
Study: NCT05789121

Intervention type: DEVICE
Intervention: walking 25 m in 4 different conditions
Description: The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation
Study: NCT06693752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Description: Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
Study: NCT06687980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study: NCT05002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
Study: NCT05520762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A strategy of first choice supraglottic airway
Description: See description in Arms section

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A strategy of first choice supraglottic airway
Description: See description in Arms section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A strategy of first choice endotracheal intubation
Description: See description in Arms section

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A strategy of first choice endotracheal intubation
Description: See description in Arms section
Study: NCT05849662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day
Study: NCT06110234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Specificity Induction
Description: Recalling complex scenes using the Episodic Specificity Induction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Associative Memory
Description: Recalling word/picture pairs
Study: NCT05849662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)
Study: NCT05999721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superficial parasternal intercostal plane block
Description: Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered.